Search Within

Solid Tumor Oncology Division

Formats
  1. Journal Article (10933)
  2. Meeting Abstract (9499)
  3. Review (556)
  4. Book Section (417)
  5. Editorial (336)
  6. Guidelines (158)
  7. Correspondence (118)
  8. Conference Paper (107)
  9. Research Letter (61)
  10. Miscellaneous (54)
  11. Book Whole (27)
Groups
  1. Department of Medicine (22243)
  2. GSK Faculty (5929)
  3. Genitourinary Oncology Service (5651)
  4. Survivorship Research (5226)
  5. Gastrointestinal Oncology Service (4692)
  6. Breast Medicine Service (4155)

More Groups

People
  1. Robert Motzer (1247)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (872)
  6. Leonard Saltz (792)

More People

Years
  1. 2025 (643)
  2. 2024 (1388)
  3. 2023 (1381)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1536)

More Years

Publications
  1. Journal of Clinical Oncology (5288)
  2. Annals of Oncology (1297)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (776)
  5. Journal of Thoracic Oncology (532)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5580)
  2. Elsevier Inc. (2662)
  3. American Association for Cancer Research (2327)
  4. Oxford University Press (1819)
  5. Nature Publishing Group (1044)
  6. Springer (981)

More Publishers

Results (22266)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparison of expert treatment recommendations versus community healthcare providers: Analysis from an online decision support tool for metastatic breast cancer
    Meeting Abstract

    Mayer, E. L.; Jhaveri, K. L.; Hamilton, E. P.; Kalinsky, K.; Constanzo, J. D.; Rosenthal, K. M.; Spring, L.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Treatment patterns among HCPs and concordance with expert recommendations in HER2-negative early breast cancer: Analysis of an interactive online treatment decision support tool
    Meeting Abstract

    Brandt, K. G.; Becker, M. N.; Gupta, T.; Kalinsky, K.; Spring, L.; Traina, T. A.; Yardley, D. A.; Rosenthal, K. M.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • CCNE1 amplification as marker of poor prognosis and novel therapeutic target in advanced breast cancer
    Meeting Abstract

    Marra, A.; Selenica, P.; Zhu, Y.; Safonov, A.; Razavi, P.; Roulston, A.; Koehler, M.; Curigliano, G.; Ross, D. S.; Weigelt, B.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Predicting fitness for chemotherapy in older adults with metastatic bladder cancer
    Meeting Abstract

    Russell, B.; Fein, D. E. C.; Berg, S. A.; Gupta, S.; Rosenberg, J. E.; Choueiri, T. K.; Bellmunt, J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • REZILIENT2: Phase 2 study of zipalertinib in patients with advanced non-small cell lung cancer (NSCLC) with exon 20 insertions (ex20ins) and other uncommon epidermal growth factor receptor (EGFR) mutations
    Meeting Abstract

    Yu, H. A.; Besse, B.; Nishio, M.; Cheng, L.; Wei, Y.; Wacheck, V.; Heymach, J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations
    Meeting Abstract

    Yu, H. A.; Besse, B.; Nishio, M.; Cheng, Y.; Wei, L.; Wacheck, V.; Heymach, J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • TTF-1 negativity as a biomarker of outcomes to immunotherapy, chemoimmunotherapy, and KRAS G12C inhibitors in lung adenocarcinoma
    Meeting Abstract

    Di Federico, A.; Hong, L.; Elkrief, A.; Thummalapalli, R.; Cooper, A. J.; Shaverdian, N.; Ricciuti, B.; Alessi, J. V. M.; De Giglio, A.; Pecci, F.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 1 results of the WEE1 inhibitor, azenosertib, in combination with gemcitabine (gem) in adult and pediatric patients (pts) with relapsed or refractory (R/R) osteosarcoma
    Meeting Abstract

    Avutu, V.; Livingston, J. A.; Federman, N.; Cranmer, L. D.; Gaspar, N.; Toulmonde, M.; Pressey, J. G.; Brahmi, M.; Poklepovic, A. S.; Shi, Q.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab
    Meeting Abstract

    Kyi, C.; Van Dongen, M.; Rottey, S.; Bermejo, I. M.; Mittag, D.; Gouveia, D.; Bol, K.; Yan, C.; Joe, A. K.; Laus, G.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2-early breast cancer (EBC) treated with endocrine therapy (ET) in the US
    Meeting Abstract

    Razavi, P.; Ahmed, M.; Roush, A.; Parikh, R.; Hitchens, A.; Shen, S.; Safonov, A.; Jhaveri, K. L.; Robson, M. E.; Peacock, N. W.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save